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platin (c21,126), the same regimen was also the most expensive in the second line 
(c13,366), irinotecan/cetuximab in the third line (c25,633), and FOLFIRI/cetuximab 
in the fourth line (c6479). CONCLUSIONS: New chemotherapeutic agents are associ-
ated with improvements in survival time but also with substantial costs. Factors 
inﬂ uencing the selection of chemotherapy included: previous therapies, course of the 
disease, the patient’s performance status, adverse events after previous chemothera-
pies, and concomitant diseases. However, open-ended coverage policies for new che-
motherapeutic agents may prove difﬁ cult to sustain as costs continue to rise.
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OBJECTIVES: To describe chemotherapy regimens used in the ﬁ rst-, second-, third-, 
and fourth-line treatment of patients with metastatic colorectal cancer and to estimate 
costs of chemotherapy regimens, supportive care, and medical procedures in Slovenia 
(part of a multinational study in central Europe). METHODS: In this opinion-based 
study, necessary data were collected by online questionnaire. All information concern-
ing treatment of colorectal cancer was based on experts opinion from an oncology 
center in Slovenia. Oncologist had access to medical records of approximately 800 
patients treated in year 2008. RESULTS: The most commonly used regimen in the 
ﬁ rst line (30% of patients) was XELIRI (capecitabine, irinotecan) + bevacizumab. The 
most commonly prescribed regimen in the second (28%) and third lines (12%) was 
XELOX (capecitabine, oxaliplatin) + bevacizumab. XELIRI + bevacizumab was most 
commonly used in the fourth line (6%). Supportive care was not used in the ﬁ rst line 
with 9%, 55%, and 76% receiving it in the second, third, and fourth lines, respec-
tively. The most common treatment algorithm (21% of patients) was ﬁ rst-line XELIRI 
+ bevacizumab and second-line XELOX + bevacizumab. Mean regimen costs per 
patient were estimated from a public payer perspective. FOLFOX + cetuximab was 
the most expensive regimen in all lines. Costs of this regimen were c35,896 in the ﬁ rst 
line and c36,179 in the second, third, and fourth lines. CONCLUSIONS: More than 
50% of patients received an active treatment until the second line. Costs of treatment 
vary between lines. New chemotherapeutic agents are associated with improvements 
in survival time but also with substantial costs. Factors inﬂ uencing the selection of 
chemotherapy included: previous therapies, course of the disease, the patient’s perfor-
mance status, adverse events after previous chemotherapies, and concomitant diseases. 
However, open-ended coverage policies for new chemotherapeutic agents may prove 
difﬁ cult to sustain as costs continue to rise.
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OBJECTIVES: Colorectal cancer (CRC) is one of the most common forms of cancer 
in western countries and represents the second leading cause of cancer mortality in 
Europe (AIRTUM 2009). Early detection and removal of cancerous lesions can reduce 
CRC and mortality and improve patients’ quality of life (Taupin et al. 2006). The 
main literature on this topic refers to the United States and few studies have been 
conducted in Italy to date (Zappa et al. 1997; Tappenden 2007). Aim of the paper is 
to shed some light on the effectiveness and costs of screening programs in the Italian 
health-care system, presenting the results of a cost-effectiveness analysis of a CRC 
screening program in Italy. METHODS: We use as case study a Regional CRC screen-
ing program to determine the full costs and the effectiveness of the adopted techniques, 
FOBT combined with colonoscopy.The costs involved in each phase of the program 
are evaluated using a microcosting analysis. Effectiveness is valued in terms of early 
detected lesions and years of life gained. Cost and effectiveness data are used to 
estimate the costs for year of life gained, using a MISCAN-COLON Model© to simu-
late and compare two alternative scenarios, with or without the screening program. 
RESULTS: The preliminary results show that the screening will prevent almost 2.0 
deaths (11.2%) per 1000 screened individuals, corresponding to 19.4 years of life 
gained in 30 years with an incremental cost-effectiveness ratio of c2.400 for life-year 
gained. CONCLUSIONS: The results outpace those of previous studies (Sonnenberg 
2000), signaling an increasing effectiveness of CRC screening program. Besides, the 
paper highlights the importance of implementing a screening not only for the effects 
that prevention can have in clinical terms, but also for the economic impact of such 
a policy in relation to the long-term sustainability of health-care systems.
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OBJECTIVES: The objective of the study was to examine the direct medical cost of 
XELOX (capecitabine plus oxaliplatin) compared to FOLFOX (ﬂ uorouracil/leucovo-
rin plus oxaliplatin) for the treatment of advanced colon-rectum cancer in China. 
METHODS: Since the equal efﬁ cacy was already demonstrated by the published lit-
erature and local clinical guideline, cost minimization analysis was performed to 
compare the direct medical costs of XELOX and FOLFOX for the treatment of 
advanced colon-rectum cancer. The direct medical costs were associated with the drug 
costs, drug administration costs, hospitalization costs, and adverse events management 
costs. The costs were calculated based on a questionnaire survey from an expert panel 
of 23 pharmacists and 10 gastrointestinal surgeons and medical oncologists. 
RESULTS: According to the recommendation of expert panel, the standard treatment 
duration of XELOX and FOLFOX was eight cycles and 12 cycles, respectively. The 
drug cost of XELOX regimen was CNY 47,306 (US$6926), higher than FOLFOX by 
CNY 22,118 (US$3238). However, the cost increment of XELOX regimen was offset 
by the higher drug administration cost (deviation CNY 6,820), hospitalization cost 
(deviation CNY 10,200), and adverse events management cost (deviation CNY 7,710) 
of FOLFOX regimen. As a result, XELOX showed a signiﬁ cant overall cost savings 
of CNY 2612 (US$382) compared with FOLFOX. CONCLUSIONS: According to 
the study, XELOX is cost saving in comparison with FOLFOX for the treatment of 
advanced colon-rectum cancer in China, especially in the chemotherapy administra-
tion and hospitalization utilization.
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OBJECTIVES: To describe treatment patterns, resource use, and associated costs for 
cancer patients with malignant ascites (MA) receiving paracentesis in Germany. 
METHODS: The study was conducted as an observational, multicenter, prevalence-
based cohort study. Inclusion criteria were: age ≥18 years, diagnosis of ovarian or 
gastrointestinal carcinoma (CA) with MA, paracentesis as treatment option for MA 
at the time of enrolment. Resource consumption data were collected by chart review 
and patient questionnaire covering the time period from the ﬁ rst paracentesis docu-
mented in the study until ascites diagnosis retrospectively and subsequent paracenteses 
prospectively. Direct medical costs were analyzed from third-party payers’ (TPP) and 
patients’ perspective. RESULTS: A total of 29 patients (38% male) with a mean age 
of 65 ± 9 years were enrolled at 11 centers (six hospitals, ﬁ ve ofﬁ ce-based practices) 
between July 2008 and August 2009. Seven patients had ovarian CA (24%), 5 gastric 
CA (17%), and 17 other gastrointestinal CAs (59%). a total of 101 paracenteses were 
documented for all patients. From ascites diagnosis to death patients received on 
average 4.6 paracenteses. Mean time between two paracenteses was 11.9 ± 12.3 days. 
Data from 42 paracenteses were eligible for resource and cost analysis. Diuretics were 
applied in 57% of paracentesis units and human albumin in 29%. Intraperitoneal 
chemotherapy was applied rarely (5%). From TPPs’ perspective, mean total costs per 
paracentesis unit amounted to c1064 ± 1453, from patients’ perspective c17 ± 46. 
Direct medical costs per paracentesis unit varied from c671 ± 1070 at ofﬁ ce-based 
practices to c2.742 ± 1.535 at hospitals (inpatient treatment). CONCLUSIONS: This 
is the ﬁ rst comprehensive study evaluating the burden of MA in cancer patients 
undergoing paracentesis in Germany. Our ﬁ ndings indicate that the costs for paracen-
tesis range around c670 to c2700 depending on health-care setting. Our results might 
serve as a basis for further research on the economic implication of malignant ascites.
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OBJECTIVES: To assess the cost-effectiveness in Germany of primary prophylaxis 
(PP) with pegﬁ lgrastim versus 6- or 11-day ﬁ lgrastim (F6, F11) in the prevention of 
febrile neutropenia (FN) in non-Hodgkin lymphoma (NHL) patients receiving 
CHOP-14 chemotherapy and in breast cancer (BC) patients receiving TAC chemo-
therapy. METHODS: A payer perspective Markov model of febrile neutropenia pro-
phylaxis in chemotherapy patients was developed. PP was deﬁ ned as initiating 
prophylaxis with the ﬁ rst chemotherapy cycle. Model cycle length matches chemo-
therapy cycle length (CHOP-14:14 days, TAC: 21 days); model time horizon is the 
duration of chemotherapy (6 cycles). Cycle 1 FN risk with no prophylaxis was esti-
mated to be 21% for NHL CHOP-14 and 14% for BC TAC; all cycle relative risks 
of FN versus no prophylaxis for PP using Pegﬁ lgrastim, F6, and F11 were 0.25, 0.87 
and 0.61, respectively, based on published literature and meta-analyses. Pegﬁ lgrastim 
cost was estimated as c1686 per chemotherapy cycle; corresponding costs for F6 and 
F11 were c1347 and c2469 based on German national pricing. Incremental cost-
effectiveness ratios (ICERs) were calculated per FN events avoided. Costs and out-
comes were discounted (3%/year). Sensitivity analyses were performed. RESULTS: 
For NHL FN events per patient were 0.15, 0.76, and 0.47 for Pegﬁ lgrastim, F6, and 
F11, respectively. ICER for Pegﬁ lgrastim versus F6 was c1386 per FN avoided. For 
BC, corresponding FN events per patient were 0.09, 0.43, and 0.27. The ICER for 
Pegﬁ lgrastim versus F6 was c6651 per FN avoided. Pegﬁ lgrastim was dominant (less 
costly, more effective) compared with F11 in both populations. Results were most 
sensitive to baseline risk of FN, cost of prophylaxis and cost of FN events. CONCLU-
SIONS: Primary prophylaxis with pegﬁ lgrastim costs <c1400 per additional FN 
